-
(BPAX) Mcap 55 M /Cash 70 M /FDA DECISION 14 FEB 2012
Bio-T-Gel™ is a once-daily transdermal testosterone gel in development for the treatment of male hypogonadism, or low testosterone levels. Male hypogonadism generally is characterized by impotence, a lack of sex drive, muscle weakness and osteoporosis. In 2010, the transdermal testosterone market for men in the U.S. was over $1.2 billion.
Bio-T-Gel™ is licensed to Teva Pharmaceuticals, USA. A Bio-T-Gel™ NDA is pending with the FDA having a PDUFA date of February 14, 2012. Teva is responsible for all regulatory and marketing activities.
Posting Permissions
- You may not post new threads
- You may not post replies
- You may not post attachments
- You may not edit your posts
Forum Rules